Trial Profile
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary)
- Indications Adenocarcinoma; Chondrosarcoma; Chordoma; Peripheral nervous system neoplasms; Renal cell carcinoma; Rhabdoid tumour; Sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Sponsors Epizyme
- 31 Dec 2023 This trial has been completed in France,according to European Clinical Trials Database record
- 21 Sep 2023 Planned End Date changed from 1 Dec 2024 to 1 Jun 2024.
- 17 Jan 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2024.